Clinical ResearchHeart FailureIncidence of Heart Failure or Cardiomyopathy After Adjuvant Trastuzumab Therapy for Breast Cancer
Heart Failure
Under an Elsevier user license
open archive
Key Words
anthracycline
cardiomyopathy
chemotherapy
epidemiology
heart failure
trastuzumab
Abbreviations and Acronyms
A+T
anthracycline plus trastuzumab
CI
confidence interval
CM
cardiomyopathy
HF
heart failure
ICD-9-CM
International Classification of Disease-9th Revision-Clinical Modification
IRR
incidence rate ratio
LVEF
left ventricular ejection fraction
SEER
Surveillance, Epidemiology, and End Results
Cited by (0)
This work was funded by an American Heart Association Grant-in-Aid Award (12GRNT9580005) and by a collaborative agreement sponsored by the Cardiology Service of Memorial Sloan-Kettering Cancer Center. Dr. Chen is supported by an Agency for Healthcare Research and Quality Career Development Award (1K08HS018781-01). Dr. Hurria is a consultant to Celegene, GlaxoSmithKline, Abraxis Bioscience, GTX, AMGEN, and Genentech. Dr. Steingart is a member of the Cardiac Safety Review Committee for Celgene. Dr. Gross has received research-related funding from Medtronic and serves on the Scientific Advisory Board of Fair Health, Inc. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Copyright © 2012 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.